Exploration of glycosyltransferases mutation status in cervical cancer reveals PARP14 as a potential prognostic marker

Glycoconj J. 2023 Oct;40(5):513-522. doi: 10.1007/s10719-023-10134-7. Epub 2023 Aug 31.

Abstract

This study investigates the potential role of Glycosyltransferases (GTs) in the glycosylation process and their association with malignant tumors. Specifically, the study focuses on PARP14, a member of GTs, and its potential as a target for tumors in the diagnosis and treatment of cervical cancer. To gather data, the study used somatic mutation data, gene expression data and clinical information from TCGA-CESE dataset as well as tissue samples from cervical cancer patients. Further verification was conducted through RT-qPCR and immunohistochemistry staining on cervical cancer tissues to confirm the expression of PARP14. The study utilized Kaplan-Meier for survival analysis of cervical cancer patient and found significant mutational abnormalities in GTs. The high frequency mutated gene was identified as PARP14. RT-qPCR revealed significantly higher mRNA expression of PARP14 compared to precancerous tissue. Using IHC combined with Kaplan-Meier,patients in the PARP14 high expression group had a better prognosis than the low expression group. The study identified PARP14 as a frequently mutated gene in cervical cancer and proposed its potential role in diagnosis and treatment.

Keywords: Cervical Cancer; Glycosyltransferase (GT); Mutation; PARP14 (poly (ADP-ribose) polymerase member 14).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Glycosyltransferases / genetics
  • Humans
  • Mutation
  • Poly(ADP-ribose) Polymerases* / genetics
  • Poly(ADP-ribose) Polymerases* / metabolism
  • Prognosis
  • Uterine Cervical Neoplasms* / diagnosis
  • Uterine Cervical Neoplasms* / genetics

Substances

  • Poly(ADP-ribose) Polymerases
  • Glycosyltransferases
  • PARP14 protein, human